Brookstone Capital Management’s Novavax NVAX Stock Holding History

Brookstone Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-505	Closed	-$6K	–	467
2019 Q1	$6K	Hold	505	–	–	﹤0.01%	399
2018 Q4	$19K	Buy	505 +5	+1%	+$194	﹤0.01%	304
2018 Q3	$19K	Hold	500	–	–	﹤0.01%	399
2018 Q2	$13K	Hold	500	–	–	﹤0.01%	368
2018 Q1	$21K	Sell	500 -61	-11%	-$2.45K	﹤0.01%	343
2017 Q4	$14K	Hold	561	–	–	﹤0.01%	308
2017 Q3	$13K	Hold	561	–	–	﹤0.01%	325
2017 Q2	$13K	Buy	+561	New	+$11K	﹤0.01%	310
2015 Q4	–	Sell	-61	Closed	-$9K	–	648
2015 Q3	$9K	Sell	61 -3	-5%	-$673	﹤0.01%	1198
2015 Q2	$14K	Buy	+64	New	+$11.3K	﹤0.01%	1035

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brookstone Capital Management's NVAX Position: Q2 2019 in Review

Brookstone Capital Management sold out of Novavax (NVAX) in Q2 2019, closing a stake of 505 shares — an estimated $6K sold.

Brookstone Capital Management first reported a position in NVAX in Q2 2015 and held it in 10 quarters. The position peaked at $21K in Q1 2018. 81 funds tracked by Wall St. Rank hold NVAX as of Q2 2019.

Brookstone Capital Management reported no remaining Novavax position as of Q2 2019 after selling out during the quarter.
Brookstone Capital Management sold 505 Novavax shares in Q2 2019, an estimated $6K.
Brookstone Capital Management first reported a position in Novavax in Q2 2015 and held it in 10 quarters.
Brookstone Capital Management's Novavax position peaked at $21K in Q1 2018.
81 funds tracked by Wall St. Rank held Novavax as of Q2 2019.

Based on Brookstone Capital Management's 13F filing for Q2 2019, filed 25 Jul 2019.